Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jun;41(6):2487-91.
doi: 10.1128/JCM.41.6.2487-2491.2003.

High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands

Arjanne Van Griethuysen  1 , Annemarie Van 't Veen, Anton Buiting, Timothy Walsh, Jan Kluytmans
Affiliations

High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands

Arjanne Van Griethuysen et al. J Clin Microbiol. 2003 Jun.

Abstract

While testing the in vitro activities of 14 antimicrobial agents against 107 methicillin-susceptible Staphylococcus aureus (MSSA) and 250 methicillin-resistant S. aureus (MRSA) isolates collected in The Netherlands, we found to our surprise that 19 (7.6%) MRSA isolates were suspected of having reduced susceptibilities to the glycopeptides when the Etest system (AB Biodisk, Solna, Sweden) was used with a large inoculum (no. 2 McFarland standard) and an extended incubation time (48 h) on brain heart infusion agar for MIC testing. Eventually, 15 of these isolates were classified as heterogeneously resistant to glycopeptides (heterogeneously glycopeptide-intermediate S. aureus [hGISA] isolates) according to the population analysis profile-area under the curve analysis. The MICs at which 50 and 90% of isolates are inhibited obtained with the Etest system with the large inoculum were as follows: for MSSA isolates, 3.0 and 4.0 micro g/ml, respectively, for both teicoplanin and vancomycin; for MRSA isolates, 3.0 and 8.0 micro g/ml, respectively, for teicoplanin, and 3.0 and 4.0 micro g/ml, respectively, for vancomycin. This is the first report of hGISA isolates in The Netherlands.

PubMed Disclaimer

References

    1. Cercenado, E., F. García-Garotte, and E. Bouza. 2001. In vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J. Antimicrob. Chemother. 47:77-81. - PubMed
    1. De Neeling, A. J., W. J. van Leeuwen, L. M. Schouls, C. S. Schot, A. van Veen-Rutgers, A. J. Beunders, A. G. M. Buiting, C. Hol, E. E. J. Ligtvoet, P. L. Petit, L. J. M. Sabbe, A. J. A. van Griethuysen, and J. D. A. van Embden. 1998. Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989-1995. J. Antimicrob. Chemother. 41:93-101. - PubMed
    1. Denis, O., C. Nonhoff, B. Byl, C. Knoop, S. Bobin-Dubreux, and M. J. Struelens. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J. Antimicrob. Chemother. 50:383-391. - PubMed
    1. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, M. Beach, and the SENTRY Participants Group. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S114-S132. - PubMed
    1. Eltringham, I. 1997. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J. Hosp. Infect. 35:1-8. - PubMed

LinkOut - more resources